Bar Harbor BioTechnology announces the release of XenoQ™ Assays

January 19, 2010 - Trenton, Maine - Bar Harbor BioTechnology, Inc. announced the release of XenoQ™ Assays today for quantitation of human tumor response in xenograft experiments. These assays enable cancer researchers to measure the efficacy an experimental drug has on human tumor tissue. Coupling an innovative combination of quantitative PCR primer design and their Global Pattern Recognition™ analysis, Bar Harbor BioTechnology provides a new way to accurately measure gene expression and gene copy number variation in human cancer cells without cross reactivity of other species. This is a critical breakthrough for cancer research that involves xenograft experiments.

It is common for drug discovery companies that test experimental drugs in mice or other species to have favorable preclinical results. However, when the experimental cancer fighting drugs are transitioned to clinical phase trials with patients, the failure rate can be significantly high. These failures can cost companies precious time and resources in the pursuit of a drug that will cure cancer.

Measuring the response a human tumor has to an experimental drug will be done faster and more accurately using XenoQ™ Assays while significantly reducing the experimental costs of the preclinical trials. "Now researchers will be able to measure the effectiveness a drug may have on a human tumor and detect if there is a correlation of dosage to gene copy number variations found in a patient's cells," said Dan Shaffer, Vice President of Bar Harbor BioTechnology, Inc. By eliminating the gene expression signal of a host species, Bar Harbor BioTechnology hopes that their new assays will dramatically increase the success rate of human clinical trials of new experimental cancer fighting drugs.

The assays will be available exclusively through a partnership that Bar Harbor BioTechnology has with Lonza Corporation. "We believe our partnership with Lonza and their global distribution channels will greatly accelerate delivering these exciting new tools into the laboratories that are researching every type of cancer", replied Robert Phelps, President and CEO of Bar Harbor BioTechnology, Inc. "We are very excited about the potential our XenoQ™ Assays will have on cancer research".

About Bar Harbor BioTechnology, Inc.
Bar Harbor BioTechnology, Inc. is a privately held company founded in 2006 and located in the downeast section of Maine. The company launched its flagship products, GeneSieve™, StellARray™ and Global Pattern Recognition™ in 2007. The StellARray™ and XenoQ™ systems are distributed by Lonza Corporation under an exclusive global distribution agreement that was created in 2008. The StellARray™ system was recently used to identify a drug that shows the reversal of Type 1 Diabetes in mouse models.

For more information, please contact Robert Phelps at:

http://www.bhbio.com

©2010 Bar Harbor BioTechnology Inc. All rights reserved.

Bar Harbor BioTechnology, Inc. undertakes no obligation to release publicly the results of any revisions to any forward-looking statement made or implied in this release, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated accordingly.

Contact:
Robert Phelps
Bar Harbor BioTechnology
18 River Field Road
Trenton, ME 04605
207-667-7900 Ext. 400